Treace Medical Concepts Quarterly Income Statements Chart
Quarterly
|
Annual
Treace Medical Concepts Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenue | 47,387,000 | 52,570,000 | 68,708,000 | 45,086,000 | 44,455,000 | 51,108,000 | 62,212,000 | 40,758,000 | 41,953,000 | 42,195,000 | 49,769,000 | 33,055,000 | 29,967,000 | 29,047,000 | 33,439,000 | 21,619,000 | 20,654,000 | 18,707,000 |
| yoy | 6.60% | 2.86% | 10.44% | 10.62% | 5.96% | 21.12% | 25.00% | 23.30% | 40.00% | 45.26% | 48.84% | 52.90% | 45.09% | 55.27% | ||||
| qoq | -9.86% | -23.49% | 52.39% | 1.42% | -13.02% | -17.85% | 52.64% | -2.85% | -0.57% | -15.22% | 50.56% | 10.30% | 3.17% | -13.13% | 54.67% | 4.67% | 10.41% | |
| cost of goods sold | 9,635,000 | 10,677,000 | 13,231,000 | 8,954,000 | 8,781,000 | 10,127,000 | 11,469,000 | 7,998,000 | 7,675,000 | 8,039,000 | 9,742,000 | 6,624,000 | 5,651,000 | 5,506,000 | 6,307,000 | 4,248,000 | 3,944,000 | 3,327,000 |
| gross profit | 37,752,000 | 41,893,000 | 55,477,000 | 36,132,000 | 35,674,000 | 40,981,000 | 50,743,000 | 32,760,000 | 34,278,000 | 34,156,000 | 40,027,000 | 26,431,000 | 24,316,000 | 23,541,000 | 27,132,000 | 17,371,000 | 16,710,000 | 15,380,000 |
| yoy | 5.82% | 2.23% | 9.33% | 10.29% | 4.07% | 19.98% | 26.77% | 23.95% | 40.97% | 45.09% | 47.53% | 52.16% | 45.52% | 53.06% | ||||
| qoq | -9.88% | -24.49% | 53.54% | 1.28% | -12.95% | -19.24% | 54.89% | -4.43% | 0.36% | -14.67% | 51.44% | 8.70% | 3.29% | -13.24% | 56.19% | 3.96% | 8.65% | |
| gross margin % | 79.67% | 79.69% | 80.74% | 80.14% | 80.25% | 80.19% | 81.56% | 80.38% | 81.71% | 80.95% | 80.43% | 79.96% | 81.14% | 81.04% | 81.14% | 80.35% | 80.90% | 82.22% |
| operating expenses | ||||||||||||||||||
| sales and marketing | 33,084,000 | 36,122,000 | 36,859,000 | 32,775,000 | 37,681,000 | 40,328,000 | 39,924,000 | 33,542,000 | 33,773,000 | 33,655,000 | 29,369,000 | 25,034,000 | 26,250,000 | 21,923,000 | 22,325,000 | 15,984,000 | 14,010,000 | 12,148,000 |
| research and development | 5,498,000 | 5,562,000 | 5,210,000 | 4,963,000 | 5,157,000 | 5,259,000 | 4,152,000 | 4,350,000 | 3,526,000 | 3,412,000 | 3,749,000 | 3,799,000 | 2,984,000 | 3,052,000 | 3,377,000 | 2,537,000 | 2,422,000 | 1,868,000 |
| general and administrative | 16,144,000 | 15,791,000 | 13,612,000 | 13,528,000 | 14,218,000 | 14,362,000 | 13,449,000 | 12,686,000 | 10,031,000 | 10,865,000 | 10,406,000 | 8,916,000 | 7,015,000 | 6,662,000 | 7,027,000 | 4,310,000 | 4,329,000 | 2,766,000 |
| total operating expenses | 54,726,000 | 57,475,000 | 55,681,000 | 51,266,000 | 57,056,000 | 59,949,000 | 57,525,000 | 50,578,000 | 47,330,000 | 47,932,000 | 43,524,000 | 37,749,000 | 36,249,000 | 31,637,000 | 32,729,000 | 22,831,000 | 20,761,000 | 16,782,000 |
| income from operations | -16,974,000 | -15,582,000 | -204,000 | -15,134,000 | -21,382,000 | -18,968,000 | -6,782,000 | -17,818,000 | -13,052,000 | -13,776,000 | -3,497,000 | -11,318,000 | -11,933,000 | -8,096,000 | -5,597,000 | -5,460,000 | -4,051,000 | -1,402,000 |
| yoy | -20.62% | -17.85% | -96.99% | -15.06% | 63.82% | 37.69% | 93.94% | 57.43% | 9.38% | 70.16% | -37.52% | 107.29% | 194.57% | 477.46% | ||||
| qoq | 8.93% | 7538.24% | -98.65% | -29.22% | 12.73% | 179.68% | -61.94% | 36.52% | -5.26% | 293.94% | -69.10% | -5.15% | 47.39% | 44.65% | 2.51% | 34.78% | 188.94% | |
| operating margin % | -35.82% | -29.64% | -0.30% | -33.57% | -48.10% | -37.11% | -10.90% | -43.72% | -31.11% | -32.65% | -7.03% | -34.24% | -39.82% | -27.87% | -16.74% | -25.26% | -19.61% | -7.49% |
| interest income | 775,000 | 841,000 | 899,000 | 1,067,000 | 1,376,000 | 1,535,000 | 1,709,000 | 1,570,000 | 1,968,000 | 1,479,000 | ||||||||
| interest expense | -1,321,000 | -1,311,000 | -1,314,000 | -1,313,000 | -1,312,000 | -1,317,000 | -1,304,000 | -1,296,000 | -1,282,000 | -1,285,000 | -1,311,000 | -1,190,000 | -946,000 | -951,000 | -1,028,000 | -963,000 | -1,038,000 | -1,031,000 |
| other income | 122,000 | 130,000 | 118,000 | 20,000 | 112,000 | 74,000 | 96,000 | 23,000 | 95,000 | 128,000 | -915,000 | -815,000 | -5,301,000 | -940,000 | -1,022,000 | -958,000 | -1,032,000 | -1,030,000 |
| other non-operating income | -424,000 | -340,000 | -297,000 | -226,000 | 176,000 | 292,000 | 501,000 | 297,000 | 781,000 | 322,000 | ||||||||
| net income | -17,398,000 | -15,922,000 | -501,000 | -15,360,000 | -21,206,000 | -18,676,000 | -6,281,000 | -17,521,000 | -12,271,000 | -13,454,000 | ||||||||
| yoy | -17.96% | -14.75% | -92.02% | -12.33% | 72.81% | 38.81% | ||||||||||||
| qoq | 9.27% | 3078.04% | -96.74% | -27.57% | 13.55% | 197.34% | -64.15% | 42.78% | -8.79% | |||||||||
| net income margin % | -36.71% | -30.29% | -0.73% | -34.07% | -47.70% | -36.54% | -10.10% | -42.99% | -29.25% | -31.89% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| other comprehensive income | ||||||||||||||||||
| unrealized gain on marketable securities | -7,000 | -40,000 | -94,000 | 217,000 | -95,000 | -94,000 | 311,000 | 71,000 | ||||||||||
| comprehensive loss | -17,405,000 | -15,962,000 | -595,000 | -15,143,000 | -21,301,000 | -18,770,000 | -5,970,000 | -17,450,000 | -12,434,000 | -13,483,000 | ||||||||
| net income per share | -0.28 | -0.25 | -0.01 | -0.25 | -0.34 | -0.3 | -0.1 | -0.28 | -0.2 | -0.23 | -0.07 | -0.22 | -0.31 | -0.16 | -0.13 | -0.12 | -0.1 | -0.07 |
| weighted-average shares used for eps calculation | 63,006,891 | 62,661,447 | 62,112,037 | 62,229,463 | 62,081,494 | 61,792,788 | 60,852,153 | 61,562,494 | 61,382,514 | 58,723,760 | 55,276,834 | 55,429,211 | 55,308,273 | 54,827,665 | 48,415,679 | 52,766,150 | 49,187,285 | 37,854,687 |
| debt extinguishment loss | -4,483,000 | |||||||||||||||||
| other comprehensive income: | ||||||||||||||||||
| unrealized loss on marketable securities | -163,000 | -29,000 | ||||||||||||||||
| interest and other income | 396,000 | 375,000 | 128,000 | 11,000 | 6,000 | 5,000 | 6,000 | 1,000 | ||||||||||
| net income and comprehensive loss | -9,600,750 | -12,133,000 | -17,234,000 | -9,036,000 | -6,619,000 | -6,418,000 | -5,083,000 | -2,432,000 | ||||||||||
| convertible preferred stock cumulative and undeclared dividends | -39,000 | -158,000 | ||||||||||||||||
| net income attributable to common stockholders | -4,412,000 | -12,133,000 | -17,234,000 | -9,036,000 | -6,619,000 | -6,418,000 | -5,122,000 | -2,590,000 | ||||||||||
| operating expenses: |
We provide you with 20 years income statements for Treace Medical Concepts stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Treace Medical Concepts stock. Explore the full financial landscape of Treace Medical Concepts stock with our expertly curated income statements.
The information provided in this report about Treace Medical Concepts stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.